Literature DB >> 10608785

Echoviruses and coxsackie B viruses that use human decay-accelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF.

O B Spiller1, I G Goodfellow, D J Evans, J W Almond, B P Morgan.   

Abstract

Many serotypes of echovirus (EV) and Coxsackie B virus (CBV) bind human decay-accelerating factor (DAF) and use it as a receptor for infection. Analogues for DAF have been isolated from mice and rats and characterized; these analogues have amino acid identities to human DAF of approximately 60%. EV serotypes 3, 6', 7, 11-13, and 29 and CBV serotypes 1, 3, and 5 caused hemagglutination of human erythrocytes but not rat or mouse erythrocytes, suggesting failure to bind rodent DAF. To confirm this evidence, radiolabeled viruses were incubated with transfected Chinese hamster ovary (CHO) cells that were abundantly expressing each type of DAF. Only cells that expressed human DAF bound virus. Although binding of EV and CBV was specific for human DAF, complement inhibition by DAF expressed in CHO cells was similar for each analogue.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10608785     DOI: 10.1086/315210

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Specificity of coxsackievirus B3 interaction with human, but not murine, decay-accelerating factor: replacement of a single residue within short consensus repeat 2 prevents virus attachment.

Authors:  Jieyan Pan; Lili Zhang; Lindsey J Organtini; Susan Hafenstein; Jeffrey M Bergelson
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Molecular determinants of disease in coxsackievirus B1 murine infection.

Authors:  Javier O Cifuente; María F Ferrer; Carolina Jaquenod de Giusti; Wen-Chao Song; Víctor Romanowski; Susan L Hafenstein; Ricardo M Gómez
Journal:  J Med Virol       Date:  2011-09       Impact factor: 2.327

3.  Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors.

Authors:  Ian G Goodfellow; David J Evans; Anna M Blom; Dave Kerrigan; J Scott Miners; B Paul Morgan; O Brad Spiller
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 4.  Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

5.  Sialic acid functions in enterovirus 70 binding and infection.

Authors:  David A Alexander; Kenneth Dimock
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 6.  Pathogenesis of human diffusely adhering Escherichia coli expressing Afa/Dr adhesins (Afa/Dr DAEC): current insights and future challenges.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

7.  Human diffusely adhering Escherichia coli expressing Afa/Dr adhesins that use human CD55 (decay-accelerating factor) as a receptor does not bind the rodent and pig analogues of CD55.

Authors:  Sylvie Hudault; O Brad Spiller; B Paul Morgan; Alain L Servin
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

8.  Interaction of decay-accelerating factor with coxsackievirus B3.

Authors:  Susan Hafenstein; Valorie D Bowman; Paul R Chipman; Carol M Bator Kelly; Feng Lin; M Edward Medof; Michael G Rossmann
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

9.  Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection.

Authors:  A E Zautner; U Körner; A Henke; C Badorff; M Schmidtke
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  A rapid and efficient method for studies of virus interaction at the host cell surface using enteroviruses and real-time PCR.

Authors:  Nina Jonsson; Maria Gullberg; Stina Israelsson; A Michael Lindberg
Journal:  Virol J       Date:  2009-12-07       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.